• Je něco špatně v tomto záznamu ?

Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine

C. Nössing, P. Herek, SF. Shariat, W. Berger, B. Englinger

. 2024 ; 34 (4) : 251-257. [pub] 20240410

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013397

PURPOSE OF REVIEW: Bladder cancer incidence is on the rise, and until recently, there has been little to no change in treatment regimens over the last 40 years. Hence, it is imperative to work on strategies and approaches to untangle the complexity of intra- and inter-tumour heterogeneity of bladder cancer with the aim of improving patient-specific care and treatment outcomes. The focus of this review is therefore to highlight novel targets, advances, and therapy approaches for bladder cancer patients. RECENT FINDINGS: The success of combining an antibody-drug conjugate (ADC) with immunotherapy has been recently hailed as a game changer in treating bladder cancer patients. Hence, interest in other ADCs as a treatment option is also rife. Furthermore, strategies to overcome chemoresistance to standard therapy have been described recently. In addition, other studies showed that targeting genomic alterations (e.g. mutations in FGFR3 , DNA damage repair genes and loss of the Y chromosome) could also be helpful as prognostic and treatment stratification biomarkers. The use of single-cell RNA sequencing approaches has allowed better characterisation of the tumour microenvironment and subsequent identification of novel targets. Functional precision medicine could be another avenue to improve and guide personalized treatment options. SUMMARY: Several novel preclinical targets and treatment options have been described recently. The validation of these advances will lead to the development and implementation of robust personalized treatment regimens for bladder cancer patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013397
003      
CZ-PrNML
005      
20240905133339.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MOU.0000000000001177 $2 doi
035    __
$a (PubMed)38602053
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Nössing, Christoph $u Department of Urology, Comprehensive Cancer Center
245    10
$a Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine / $c C. Nössing, P. Herek, SF. Shariat, W. Berger, B. Englinger
520    9_
$a PURPOSE OF REVIEW: Bladder cancer incidence is on the rise, and until recently, there has been little to no change in treatment regimens over the last 40 years. Hence, it is imperative to work on strategies and approaches to untangle the complexity of intra- and inter-tumour heterogeneity of bladder cancer with the aim of improving patient-specific care and treatment outcomes. The focus of this review is therefore to highlight novel targets, advances, and therapy approaches for bladder cancer patients. RECENT FINDINGS: The success of combining an antibody-drug conjugate (ADC) with immunotherapy has been recently hailed as a game changer in treating bladder cancer patients. Hence, interest in other ADCs as a treatment option is also rife. Furthermore, strategies to overcome chemoresistance to standard therapy have been described recently. In addition, other studies showed that targeting genomic alterations (e.g. mutations in FGFR3 , DNA damage repair genes and loss of the Y chromosome) could also be helpful as prognostic and treatment stratification biomarkers. The use of single-cell RNA sequencing approaches has allowed better characterisation of the tumour microenvironment and subsequent identification of novel targets. Functional precision medicine could be another avenue to improve and guide personalized treatment options. SUMMARY: Several novel preclinical targets and treatment options have been described recently. The validation of these advances will lead to the development and implementation of robust personalized treatment regimens for bladder cancer patients.
650    _2
$a lidé $7 D006801
650    12
$a nádory močového měchýře $x genetika $x terapie $x farmakoterapie $x patologie $7 D001749
650    12
$a individualizovaná medicína $x metody $7 D057285
650    _2
$a cílená molekulární terapie $x metody $7 D058990
650    _2
$a imunokonjugáty $x terapeutické užití $7 D018796
650    _2
$a nádorové biomarkery $x genetika $x metabolismus $7 D014408
650    _2
$a nádorové mikroprostředí $x účinky léků $7 D059016
650    _2
$a imunoterapie $x metody $7 D007167
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Herek, Paula $u Department of Urology, Comprehensive Cancer Center $u Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center $u Department of Urology, Weill Cornell Medical College, New York, New York $u Department of Urology, University of Texas Southwestern, Dallas, Texas, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute for Urology, University of Jordan, Amman, Jordan $u Research center for Evidence Medicine, Urology Department, Tabriz University of Medical Sciences, Tabriz, Iran $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
700    1_
$a Berger, Walter $u Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria
700    1_
$a Englinger, Bernhard $u Department of Urology, Comprehensive Cancer Center $u Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria
773    0_
$w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 34, č. 4 (2024), s. 251-257
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38602053 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133333 $b ABA008
999    __
$a ok $b bmc $g 2143296 $s 1225263
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 34 $c 4 $d 251-257 $e 20240410 $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace